Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
16 sept. 2024 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
12 sept. 2024 08h00 HE
|
Vera Therapeutics
On track to announce topline results from ORIGIN 3 trial in Q2 2025Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024 BRISBANE, Calif., Sept. 12,...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 sept. 2024 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting...
Vera Therapeutics to Participate at September Investor Conferences
29 août 2024 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 août 2024 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of...
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
08 août 2024 08h00 HE
|
Vera Therapeutics
Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN)Presented data from Phase 2b ORIGIN study at ERA24 Congress showing atacicept stabilized kidney function through 72...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2024 16h30 HE
|
Vera Therapeutics
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera’s Board of Directors granted...
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
01 juil. 2024 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
11 juin 2024 16h01 HE
|
Vera Therapeutics
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07 juin 2024 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...